A big priority of the Trump Administration is lowering drug prices, and the president’s budget accordingly contains a range of proposals for the government’s various health care programs. AAF’s Deputy Director of Health Care Policy Tara O’Neill Hayes explains these proposals and analyzes their potential effects on drug prices.

She concludes:

The president’s budget indicates a continued support for efforts to reduce drug prices and costs. Most of the proposals in this year’s budget have been proposed before, and some seem to be gaining traction and may become law this year. Some proposals will have severe negative consequences, while others are new and creative ways to address some of the complex challenges in the drug pricing space.

Read the analysis.